96 related articles for article (PubMed ID: 33922968)
1. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia.
Abramovic I; Vrhovec B; Skara L; Vrtaric A; Nikolac Gabaj N; Kulis T; Stimac G; Ljiljak D; Ruzic B; Kastelan Z; Kruslin B; Bulic-Jakus F; Ulamec M; Katusic-Bojanac A; Sincic N
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922968
[TBL] [Abstract][Full Text] [Related]
2. LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA.
Abramovic I; Pezelj I; Dumbovic L; Skara Abramovic L; Vodopic T; Bulimbasic S; Stimac G; Bulic-Jakus F; Kulis T; Katusic Bojanac A; Tomas D; Ulamec M; Sincic N
Prostate; 2024 Jun; ():. PubMed ID: 38824441
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of miR-148a-3p and miR-106a-5p as Biomarkers for Prostate Cancer: Pilot Study.
Coman RA; Schitcu VH; Budisan L; Raduly L; Braicu C; Petrut B; Coman I; Berindan-Neagoe I; Al Hajjar N
Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790213
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer.
Mazzetti S; Defeudis A; Nicoletti G; Chiorino G; De Luca S; Faletti R; Gatti M; Gontero P; Manfredi M; Mello-Grand M; Peraldo-Neia C; Zitella A; Porpiglia F; Regge D; Giannini V
Eur Radiol; 2024 Jan; ():. PubMed ID: 38177618
[TBL] [Abstract][Full Text] [Related]
5. Hyperglycemia and microRNAs in prostate cancer.
Russo V; Tamburrino L; Morselli S; Sani C; Baldi E; Sebastianelli A; Raspollini MR; Mongia A; Carradori V; Lallo E; Munnia A; Bisanzi S; Marchiani S; Visioli C; Rapi S; Serni S; Zappa M; Carozzi F; Peluso M
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38402304
[TBL] [Abstract][Full Text] [Related]
6. Validation of potential RNA biomarkers for prostate cancer diagnosis and monitoring in plasma and urinary extracellular vesicles.
Brokāne A; Bajo-Santos C; Zayakin P; Belovs A; Jansons J; Lietuvietis V; Martens-Uzunova ES; Jenster GW; Linē A
Front Mol Biosci; 2023; 10():1279854. PubMed ID: 38099195
[No Abstract] [Full Text] [Related]
7. Expression of miR-148b-3p is correlated with overexpression of biomarkers in prostate cancer.
Arámbula-Meraz E; Bergez-Hernández F; Leal-León E; Romo-Martínez E; Picos-Cárdenas V; Luque-Ortega F; Romero-Quintana J; Alvarez-Arrazola M; García-Magallanes N
Genet Mol Biol; 2020; 43(1):e20180330. PubMed ID: 32154827
[TBL] [Abstract][Full Text] [Related]
8. Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer.
Dong L; Hu C; Ma Z; Huang Y; Shelley G; Kuczler MD; Kim CJ; Witwer KW; Keller ET; Amend SR; Xue W; Pienta KJ
Res Sq; 2024 Mar; ():. PubMed ID: 38585988
[TBL] [Abstract][Full Text] [Related]
9. Potential of miRNAs in Plasma Extracellular Vesicle for the Stratification of Prostate Cancer in a South African Population.
Temilola DO; Wium M; Paccez J; Salukazana AS; Otu HH; Carbone GM; Kaestner L; Cacciatore S; Zerbini LF
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568783
[TBL] [Abstract][Full Text] [Related]
10. Integrated grade-wise profiling analysis reveals potential plasma miR-373-3p as prognostic indicator in Prostate Cancer & its target KPNA2.
Khan MM; Sharma V; Serajuddin M; Kirabo A
Noncoding RNA Res; 2024 Sep; 9(3):954-963. PubMed ID: 38699204
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of
Karadağ A; Dirican E; Özmerdiven ÇG; Özen A; Ayan S; Kabadere S
Nucleosides Nucleotides Nucleic Acids; 2024 Apr; ():1-12. PubMed ID: 38593055
[TBL] [Abstract][Full Text] [Related]
12. Deletion in a regulatory region is associated with underexpression of miR-148b‑3p in patients with prostate cancer.
Bergez-Hernández F; Luque-Ortega F; García-Magallanes N; Alvarez-Arrazola M; Arámbula-Meraz E
Biomed Rep; 2024 Mar; 20(3):52. PubMed ID: 38357236
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-588 is upregulated in human prostate cancer with prognostic and functional implications.
Zhao N; Lin T; Zhao C; Zhao S; Zhou S; Li Y
J Cell Biochem; 2017 Oct; ():. PubMed ID: 28980707
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia.
Pérez-Rambla C; Puchades-Carrasco L; García-Flores M; Rubio-Briones J; López-Guerrero JA; Pineda-Lucena A
Metabolomics; 2017; 13(5):52. PubMed ID: 28804274
[TBL] [Abstract][Full Text] [Related]
15. Blood-Based DNA Methylation Analysis by Multiplexed OBBPA-ddPCR to Verify Indications for Prostate Biopsies in Suspected Prostate Cancer Patients.
Friedemann M; Jandeck C; Tautz L; Gutewort K; von Rein L; Sukocheva O; Fuessel S; Menschikowski M
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611002
[TBL] [Abstract][Full Text] [Related]
16. Liquid Biopsy-Based Exo-oncomiRNAs Can Predict Prostate Cancer Aggressiveness.
Ruiz-Plazas X; Altuna-Coy A; Alves-Santiago M; Vila-Barja J; García-Fontgivell JF; Martínez-González S; Segarra-Tomás J; Chacón MR
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33440913
[TBL] [Abstract][Full Text] [Related]
17. miR-17-3p Downregulates Mitochondrial Antioxidant Enzymes and Enhances the Radiosensitivity of Prostate Cancer Cells.
Xu Z; Zhang Y; Ding J; Hu W; Tan C; Wang M; Tang J; Xu Y
Mol Ther Nucleic Acids; 2018 Dec; 13():64-77. PubMed ID: 30240971
[TBL] [Abstract][Full Text] [Related]
18. Multi-omic diagnostics of prostate cancer in the presence of benign prostatic hyperplasia.
Spick M; Muazzam A; Pandha H; Michael A; Gethings LA; Hughes CJ; Munjoma N; Plumb RS; Wilson ID; Whetton AD; Townsend PA; Geifman N
Heliyon; 2023 Dec; 9(12):e22604. PubMed ID: 38076065
[TBL] [Abstract][Full Text] [Related]
19. Datasets for next-generation sequencing of DNA and RNA from urine and plasma of patients with prostate cancer.
Nikitina AS; Sharova EI; Danilenko SA; Selezneva OV; Butusova TB; Vasiliev AO; Govorov AV; Prilepskaya EA; Pushkar DY; Kostryukova ES
Data Brief; 2017 Feb; 10():369-372. PubMed ID: 28018951
[TBL] [Abstract][Full Text] [Related]
20. Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.
Balázs K; Antal L; Sáfrány G; Lumniczky K
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33924671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
